This activation leads to increased insulin production, reduced appetite, and support for weight loss
They are not intended to diagnose, treat, cure, or prevent any disease.
Further reading FcRn blockade in CIDP (ADHERE trial) The Lancet Neurology 2024 #PatientEducation #CIDP #Neuromuscular #EvidenceBasedMedicine Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial thelancet.com To view or add a comment, sign in Platelet Hyperreactivity: A Novel Peripheral Biomarker for Preclinical Alzheimers
At the same time, the pleiotropic, neurotrophic and neuroprotective properties of GLP-1RAs are also obvious and, taking into account the ability to enhance the energy metabolism of neurons and optimize synaptic plasticity these beneficial effects position GLP-1RAs as potential agents modifying brain diseases [109, 110]